secwatch.observer — SEC 8-K summary
======================================

Issuer:     INFINITY PHARMACEUTICALS, INC. (—)
CIK:        0001113148
Form:       8-K
Filed at:   2023-07-25T23:59:59+00:00
Accession:  0001140361-23-036062
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Infinity Pharma cuts 78% of workforce, three directors resign, seeks strategic alternative for eganelisib
--------------------------------------------------------------------------------

- Headcount reduced by 21 positions (78% of workforce); expects $3.4M severance charge in Q3 2023.
- Three board members (Agresta, Kango, Schwartz) resign; remaining five directors serve without compensation.
- Company hires SSG Capital Advisors to lead strategic process to maximize value of eganelisib.
- Company evaluating withdrawal of Nasdaq delisting appeal; withdrawal likely leads to stock delisting.
- Merger agreement with MEI Pharma terminated; seeking alternative strategic transaction for eganelisib.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1113148/000114036123036062/0001140361-23-036062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1113148/000114036123036062/brhc20056430_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-036062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer